Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ataibeckley Inc's Business Segments
Ataibeckley Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Research and development services revenue
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Research and development services revenue100%
- Research and development services revenue Reportable Aggregation before Other Segment100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Research and development services revenue | $ 1 | 100% |
| Research and development services revenue Reportable Aggregation before Other Segment | $ 1 | 100% |
Annual Results
Revenue Share by Reportable Segment - FY
- Research and development services revenue100%
- Research and development services revenue Reportable Aggregation before Other Segment100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Research and development services revenue | $ 1 | 100% |
| Research and development services revenue Reportable Aggregation before Other Segment | $ 1 | 100% |
Description of Ataibeckley Inc
Atai Life Sciences N.V. is a leading biopharmaceutical company that focuses on developing transformative therapies for mental health disorders. The company's mission is to improve the lives of individuals suffering from conditions such as depression, anxiety, addiction, and other mental illnesses.
Atai Life Sciences was founded in 2018 and is based in Amsterdam, Netherlands. It has quickly gained recognition for its innovative approach to drug development and its commitment to addressing unmet needs in mental health treatment. The company operates a unique model that combines in-house drug discovery and development capabilities with external partnerships and collaborations.
One of the key aspects that sets Atai Life Sciences apart is its focus on psychedelic compounds. The company believes that these compounds hold great promise in treating mental health disorders when used in conjunction with therapy and support systems. Atai is actively researching and developing psychedelic-based therapeutics to identify effective treatments for various conditions.
Atai has a portfolio of subsidiary companies, each working on specific therapeutic areas and utilizing different approaches. For example, one subsidiary, Compass Pathways, is focused on developing psilocybin-based therapies for treatment-resistant depression. Another subsidiary, Perception Neuroscience, is working on enhanced delivery mechanisms for drugs targeting mental health disorders.
In addition to its work in the field of psychedelics, Atai is also involved in developing non-psychedelic compounds for mental health treatment. The company is exploring novel approaches and innovative drug candidates for conditions such as substance use disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD).
Atai has a strong network of partnerships and collaborations with academic institutions, research organizations, and other companies. This allows them to leverage the expertise and resources of various stakeholders in advancing their drug development programs. The company is also actively engaged in clinical trials to evaluate the safety and efficacy of its experimental therapeutics.
Atai Life Sciences is committed to ensuring that its therapies are accessible to those who need them the most. The company recognizes the importance of addressing the global burden of mental health and is dedicated to developing affordable and scalable treatments. They aim to create a future in which mental health disorders are treated with the same level of importance and urgency as physical illnesses.
Overall, Atai Life Sciences N.V. is at the forefront of revolutionizing mental healthcare through its groundbreaking research and development efforts. The company's focus on psychedelic compounds, innovative approaches, and commitment to improving patient outcomes make it a leading player in the mental health space.
Atai Life Sciences was founded in 2018 and is based in Amsterdam, Netherlands. It has quickly gained recognition for its innovative approach to drug development and its commitment to addressing unmet needs in mental health treatment. The company operates a unique model that combines in-house drug discovery and development capabilities with external partnerships and collaborations.
One of the key aspects that sets Atai Life Sciences apart is its focus on psychedelic compounds. The company believes that these compounds hold great promise in treating mental health disorders when used in conjunction with therapy and support systems. Atai is actively researching and developing psychedelic-based therapeutics to identify effective treatments for various conditions.
Atai has a portfolio of subsidiary companies, each working on specific therapeutic areas and utilizing different approaches. For example, one subsidiary, Compass Pathways, is focused on developing psilocybin-based therapies for treatment-resistant depression. Another subsidiary, Perception Neuroscience, is working on enhanced delivery mechanisms for drugs targeting mental health disorders.
In addition to its work in the field of psychedelics, Atai is also involved in developing non-psychedelic compounds for mental health treatment. The company is exploring novel approaches and innovative drug candidates for conditions such as substance use disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD).
Atai has a strong network of partnerships and collaborations with academic institutions, research organizations, and other companies. This allows them to leverage the expertise and resources of various stakeholders in advancing their drug development programs. The company is also actively engaged in clinical trials to evaluate the safety and efficacy of its experimental therapeutics.
Atai Life Sciences is committed to ensuring that its therapies are accessible to those who need them the most. The company recognizes the importance of addressing the global burden of mental health and is dedicated to developing affordable and scalable treatments. They aim to create a future in which mental health disorders are treated with the same level of importance and urgency as physical illnesses.
Overall, Atai Life Sciences N.V. is at the forefront of revolutionizing mental healthcare through its groundbreaking research and development efforts. The company's focus on psychedelic compounds, innovative approaches, and commitment to improving patient outcomes make it a leading player in the mental health space.
Atai Life Sciences N.V. is a biotechnology company focused on developing novel therapeutics for mental health disorders. The company adopts an asset-centric approach, developing a pipeline of substance and treatment modalities that leverage the therapeutic potential of psychedelic substances and other innovative approaches. Here’s an extensive look at the segments, products, and services the company offers:
Segments
1. Psychedelic Therapeutics: Atai Life Sciences is primarily engaged in the research and development of psychedelic compounds intended to treat mental health conditions. This segment encompasses various compounds derived from naturally occurring psychedelics or developed through synthetic processes.
2. Biotechnology Innovations: Aside from psychedelics, Atai is also investing in other biopharmaceutical innovations aimed at addressing unmet needs in mental health treatment. This includes a wider spectrum of neurotherapeutics.
3. Digital Platforms: To complement their therapeutic offerings, Atai explores the integration of digital health platforms designed to enhance treatment adherence, measure outcomes, and support the therapeutic journey of patients.
Products and Services
1. Ketamine Programs: Atai is involved in developing treatments utilizing ketamine, a well-known anesthetic that has shown rapid antidepressant effects in treatment-resistant depression. The company is working on optimizing the delivery of ketamine through various formulations and treatment protocols.
2. Psilocybin Research: The company conducts research on psilocybin, a psychedelic compound found in certain mushrooms, exploring its efficacy in treating depression, anxiety, and substance use disorders.
3. MDMA and Other Psychedelics: Atai explores the potential of MDMA and other psychedelic substances in therapy, particularly for conditions like PTSD and addiction, leveraging the unique therapeutic, empathogenic properties of these substances.
4. Partnerships for Development: Atai often collaborates with academic institutions and other biopharmaceutical companies to further its research and development goals. These partnerships may involve co-developing compounds, sharing research expertise, or advancing clinical studies.
5. Clinical Trial Services: The company participates in the design and execution of clinical trials to test the efficacy, safety, and optimal dosing of its novel compounds. It may provide services related to regulatory compliance, data management, and patient monitoring during clinical studies.
6. Mental Health Platform: As part of its digital health initiatives, Atai aims to provide a comprehensive mental health platform that may include teletherapy services, guidance for patients, and tools to assess mental health outcomes.
Psychedelic-Assisted Psychotherapy: Atais offerings may extend to training programs for clinicians on the effective use of psychedelic-assisted therapies. They may develop protocols that incorporate psychotherapy with psychedelic treatment to facilitate better patient outcomes.
8. Regulatory and Compliance Consulting: Given the complex regulatory landscape surrounding psychedelics and new therapeutic modalities, Atai may offer consulting services that help navigate the approval processes, ensuring compliance with health authorities.
9. Patient Support Programs: To ensure safe and effective use of its therapies, Atai could implement support programs tailored for patients undergoing treatment, which may include educational resources, therapy support, and follow-up care.
10. Research and Development Services: Atai Life Sciences may assist other organizations through R&D services, leveraging its expertise in psychedelic substances and mental health to support drug discovery and development efforts.
Conclusion
Atai Life Sciences N.V. positions itself at the forefront of mental health innovation through a multi-faceted approach targeting various therapeutics, partnerships, and research development in both psychedelic and non-psychedelic domains. The companys focus on transformative therapeutic options aligns with the growing recognition of the need for effective treatments in addressing various mental health challenges globally.
Segments
1. Psychedelic Therapeutics: Atai Life Sciences is primarily engaged in the research and development of psychedelic compounds intended to treat mental health conditions. This segment encompasses various compounds derived from naturally occurring psychedelics or developed through synthetic processes.
2. Biotechnology Innovations: Aside from psychedelics, Atai is also investing in other biopharmaceutical innovations aimed at addressing unmet needs in mental health treatment. This includes a wider spectrum of neurotherapeutics.
3. Digital Platforms: To complement their therapeutic offerings, Atai explores the integration of digital health platforms designed to enhance treatment adherence, measure outcomes, and support the therapeutic journey of patients.
Products and Services
1. Ketamine Programs: Atai is involved in developing treatments utilizing ketamine, a well-known anesthetic that has shown rapid antidepressant effects in treatment-resistant depression. The company is working on optimizing the delivery of ketamine through various formulations and treatment protocols.
2. Psilocybin Research: The company conducts research on psilocybin, a psychedelic compound found in certain mushrooms, exploring its efficacy in treating depression, anxiety, and substance use disorders.
3. MDMA and Other Psychedelics: Atai explores the potential of MDMA and other psychedelic substances in therapy, particularly for conditions like PTSD and addiction, leveraging the unique therapeutic, empathogenic properties of these substances.
4. Partnerships for Development: Atai often collaborates with academic institutions and other biopharmaceutical companies to further its research and development goals. These partnerships may involve co-developing compounds, sharing research expertise, or advancing clinical studies.
5. Clinical Trial Services: The company participates in the design and execution of clinical trials to test the efficacy, safety, and optimal dosing of its novel compounds. It may provide services related to regulatory compliance, data management, and patient monitoring during clinical studies.
6. Mental Health Platform: As part of its digital health initiatives, Atai aims to provide a comprehensive mental health platform that may include teletherapy services, guidance for patients, and tools to assess mental health outcomes.
Psychedelic-Assisted Psychotherapy: Atais offerings may extend to training programs for clinicians on the effective use of psychedelic-assisted therapies. They may develop protocols that incorporate psychotherapy with psychedelic treatment to facilitate better patient outcomes.
8. Regulatory and Compliance Consulting: Given the complex regulatory landscape surrounding psychedelics and new therapeutic modalities, Atai may offer consulting services that help navigate the approval processes, ensuring compliance with health authorities.
9. Patient Support Programs: To ensure safe and effective use of its therapies, Atai could implement support programs tailored for patients undergoing treatment, which may include educational resources, therapy support, and follow-up care.
10. Research and Development Services: Atai Life Sciences may assist other organizations through R&D services, leveraging its expertise in psychedelic substances and mental health to support drug discovery and development efforts.
Conclusion
Atai Life Sciences N.V. positions itself at the forefront of mental health innovation through a multi-faceted approach targeting various therapeutics, partnerships, and research development in both psychedelic and non-psychedelic domains. The companys focus on transformative therapeutic options aligns with the growing recognition of the need for effective treatments in addressing various mental health challenges globally.